August 27 2020 - 09:45AM
InvestorsHub NewsWire
Alert
Share On Facebook
Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe™
Toronto, Ontario – August 27, 2020 – InvestorsHub NewsWire -- Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus (SARS-CoV-2) causing COVID-19.
Under this agreement, Therma will provide funding for the project in phases ("Phase" or "Phases") as certain developmental milestones are achieved, Therma will commit up to $300,000 for Phase 1 which will focus on the identification of anti-COVID-19 poly-peptides to be utilized in the test prototype development stage. Therma and Orpheus expect Phase 1 to take approximately 45 days to complete. Therma and Orpheus have identified several 3rd party providers to assist with the Phase 1 development path.
During Phase 2, Therma's and Orpheus' partnership with various clinical institutions will focus on clinical validation of the test prototype in up to 250 clinical samples. After Phase 2, Therma can decide to advance to Phase 3 only upon success with Phases 1 and 2. Phase 3 will include regulatory enabling studies where the Parties expect to apply for EUA approvals during Phase 3 including commercialization activities.
Upon approval by regulatory bodies of CoviSafe™, Therma and Orpheus expect to market its rapid test for use by education systems, businesses of all types, public events and other venues, sporting events or activities where a COVID-19 test is required and useful.
As stated in the Therma press release on August 20, 2020, CoviSafe™ is intended to have unique features such as high accuracy, sensitivity, and specificity while delivering results in less than 20 minutes. CoviSafe™ screens and directly detects the virus rather than its genetic material in saliva or as needed in other biological samples. It can be tested anywhere without the need for the test sample to be sent to a lab for processing by a trained technician. The test can be used alongside current testing methods in areas where laboratory access is limited or non-existent.
Additionally, Therma has negotiated terms in the co-development agreement for the right to invest in a COVID-19 therapeutic drug development program currently underway by the same management team as Orpheus' and under a separate corporate entity. Therma's participation will be by way of an equity investment to be announced at the time of investment.
Mr. Rob Fia, CEO of Therma Bright commented, "We are excited to have entered into this co-development arrangement with the Orpheus' team and its vast network of academic and clinical institution collaborators. Therma is committed to an expedited path to regulatory approval of the CoviSafe™ test by providing its expertise in medical device engineering, compliance, and regulatory affairs".
Dr. Saeid Babaei, Chairman & CEO of Orpheus Medica commented, "Orpheus can leverage the partnership with Therma by using its internal core capabilities including research and development, and clinical trial operations and validation to improve the speed, accuracy, accessibility, and affordability of COVID-19 testing, a major step in helping to prevent the spread of COVID-19. We have assembled a number of key collaborations with various industry and academic entities to innovate and accelerate our developmental timelines in addition to engaging with our trusted and established suppliers, manufacturers and service providers".
About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.
Therma Bright Inc. trades on the TSXV (TSXV: THRM). For more information visit: www.thermabright.com and www.coldsores.com.
About Orpheus Medica Inc.
Orpheus Medica is a fully integrated research-driven Canadian biotech company focused on the development and commercialization of innovative diagnostic and therapeutics for unmet medical needs. Orpheus, with its fully integrated R&D infrastructure, provides strategic partners and collaborators access to its proven and proprietary discovery and development of novel biopharmaceutical products. Our team has over 15 years of proven and validated computational capabilities for analysis and optimization of antibodies and peptides as well as small molecules.
For further information, please contact:
Therma Bright
Rob Fia, CEO
rfia@thermabright.com
Orpheus Medica
Saeid Babaei, Chairman & CEO
sbabaei@orpheusmed.com
follow me on BLUE SKY BREAKOUT
Recent THRM News
- Gentherm Wins 2024 Automotive News PACE Innovation Partnership Award • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Gentherm Reports 2024 First Quarter Results • GlobeNewswire Inc. • 04/30/2024 10:00:00 AM
- Gentherm Announces Date for 2024 First Quarter Results News Release and Conference Call • GlobeNewswire Inc. • 04/10/2024 08:30:00 PM
- Gentherm Releases 2023 Sustainability Report • GlobeNewswire Inc. • 04/01/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:36:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 10:37:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/21/2024 09:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 11:10:16 AM
- Gentherm Reports 2023 Fourth Quarter and Full Year Results • GlobeNewswire Inc. • 02/21/2024 11:00:00 AM
- Gentherm’s ClimateSense® Technology Named a Winner of the 2024 BIG Innovation Award • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/09/2024 04:21:57 PM
- Gentherm Announces Date for 2023 Fourth Quarter and Year-End Results News Release and Conference Call • GlobeNewswire Inc. • 01/25/2024 09:45:00 PM
- SourceMark Medical Announces Expanded Partnership with Gentherm Medical • PR Newswire (US) • 01/09/2024 03:00:00 PM
- Gentherm Unveils WellSense™ “A Symphony of Sensations” during CES 2024 • GlobeNewswire Inc. • 01/08/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:21:45 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:14:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 01:30:29 PM
- Gentherm Announces Laura Kowalchik as New Independent Director • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Gentherm Named a Winner of The Michigan Top Workplaces 2023 Award by The Detroit Free Press • GlobeNewswire Inc. • 11/20/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 12:16:00 PM
- Gentherm Initiates $60 Million Accelerated Share Repurchase • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 10:10:13 AM
- Gentherm Reports 2023 Third Quarter Results • GlobeNewswire Inc. • 10/26/2023 10:00:00 AM
- Gentherm’s ClimateSense® Technology Named a Winner of the Reuters D.R.I.V.E Honour for Reducing Emissions • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Gentherm to Participate in the 2023 Baird Global Industrial Conference • GlobeNewswire Inc. • 10/17/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM